Page 32 - Bioterrorism

31

Alexander S Jones concluded “we must seriously consider a laboratory origin for this virus”
because 5% of both these influenza A RNA sequences share no known homology in any public
databases.

“BLAST sequence homology of 'swine flu' indicates both the Hemagglutinin

(HA) surface protein as well as the Non-structural (NS1) interferon

Inhibition proteins are novel recombinants previously unidentified in nature.

Both these influenza proteins, based on the genetic sequences released Friday May 1st by the U.S.
Centers of Disease Control (CDC), share their closest genetic identity with turkey (avian) and pig
(swine) strains from multiple continents including North America as well as Asia. Even the closest
matches indicate 5% previously unidentified genetic material.

I submit this evidence, coupled with the lack of the presence of this virus at the pig farm near the
proposed CDC's "patient zero" (a 5 year old from La Gloria, 80km away from the pig farm in
Perote, Mexico), shows that the origin of the flu outbreak remains unidentified at this time, and
cannot be ascribed to Mexican or North American swine.

Furthermore, I submit that since 5% of both these influenza A RNA sequences share no known
homology in any public databases (in addition to the avian/swine hybrid nature of both these
critical genes), that we must seriously consider a laboratory origin for this virus.

Future research that may be promising includes identifying critical SNPs, especially in the PB2
and the NS1 coding regions which may be markers for evolution of pathogen virulence, and
should be closely monitored. The hemagglutinin protein should also be monitored for acquisition
of a poly-basic amino acid site which would give the virus pantrophic properties as in the 1918
pandemic. “(Alexander S Jones)

VII. Evidence as to the role of Baxter and WHO in producing and releasing pandemic virus
material in Austria.

Baxter Pharmaceutical http://www.baxter.com/ has been chosen by the WHO to lead the efforts in
finding a vaccine cure for the swine flu H1N1 virus.

Baxter AG, headquartered in Vienna, and the Austrian subsidiary of the pharmaceutical company
Baxter International, headquartered in Deerfield, IL, USA, sent vaccine material contaminated
with deadly live H5N1 bird flu virus to 16 laboratories in four countries in winter 2009 before a
technician caught the mistake.

The deadly mixture of live bird flu virus and human flu virus were mixed in a biosecurity level 3
facility, where basic protocol and procedures would make it impossible to ever mix a live virus
bioweapon with vaccine material by accident. In the first place, the strain of bird flu that is lethal
to humans has no place in the the Baxter facility in Austria. So what was it doing in the facility
designed for research into normal flu viruses and vaccines and their production to begin with?